List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1541402/publications.pdf Version: 2024-02-01

		9264	3732
267	37,591	74	179
papers	citations	h-index	g-index
377	200	277	52285
JZZ	JZZ	JZZ	22202
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine. Clinical Infectious Diseases, 2023, 76, e299-e307.	5.8	16
2	Role of Epithelial–Endothelial Cell Interaction in the Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Clinical Infectious Diseases, 2022, 74, 199-209.	5.8	15
3	A(H1N1)pdm09 Influenza Viruses Replicating in Ferret Upper or Lower Respiratory Tract Differed in Onward Transmission Potential by Air. Journal of Infectious Diseases, 2022, 225, 65-74.	4.0	9
4	Cellular tropism of SARS-CoV-2 in the respiratory tract of Syrian hamsters and B6.Cg-Tg(K18-ACE2)2Prlmn/J transgenic mice. Veterinary Pathology, 2022, 59, 639-647.	1.7	4
5	Probable Transmission of SARS-CoV-2 Omicron Variant in Quarantine Hotel, Hong Kong, China, November 2021. Emerging Infectious Diseases, 2022, 28, 460-462.	4.3	150
6	Comparison of the immunogenicity of <scp>BNT162b2</scp> and <scp>CoronaVac COVID</scp> â€19 vaccines in Hong Kong. Respirology, 2022, 27, 301-310.	2.3	127
7	Unresolved questions in the zoonotic transmission of MERS. Current Opinion in Virology, 2022, 52, 258-264.	5.4	17
8	Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nature Medicine, 2022, 28, 486-489.	30.7	305
9	A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 844-847.	5.6	36
10	SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature, 2022, 603, 715-720.	27.8	577
11	Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: A self-controlled case series and nested case-control study. The Lancet Regional Health - Western Pacific, 2022, 21, 100393.	2.9	41
12	Genomic epidemiology of SARS-CoV-2 under an elimination strategy in Hong Kong. Nature Communications, 2022, 13, 736.	12.8	26
13	Antibody responses to 2 doses of mRNA COVID-19 vaccine in pediatric patients with kidney diseases. Kidney International, 2022, 101, 1069-1072.	5.2	13
14	Reconstructing antibody dynamics to estimate the risk of influenza virus infection. Nature Communications, 2022, 13, 1557.	12.8	9
15	Transmission of SARS-CoV-2 delta variant (AY.127) from pet hamsters to humans, leading to onward human-to-human transmission: a case study. Lancet, The, 2022, 399, 1070-1078.	13.7	140
16	Biphasic waning of hemagglutination inhibition antibody titers after influenza vaccination in children. Journal of Infectious Diseases, 2022, , .	4.0	1
17	SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022. Eurosurveillance, 2022, 27, .	7.0	28
18	Use of Sewage Surveillance for COVID-19: A Large-Scale Evidence-Based Program in Hong Kong. Environmental Health Perspectives, 2022, 130, 57008.	6.0	20

#	Article	IF	CITATIONS
19	Reply to: CoronaVac or BNT162b2 Vaccine as a Third Dose. American Journal of Respiratory and Critical Care Medicine, 2022, , .	5.6	0
20	Evaluation of RT-qPCR Primer-Probe Sets to Inform Public Health Interventions Based on COVID-19 Sewage Tests. Environmental Science & Technology, 2022, 56, 8875-8884.	10.0	11
21	Increased Stability of SARS-CoV-2 Omicron Variant over Ancestral Strain. Emerging Infectious Diseases, 2022, 28, 1515-1517.	4.3	15
22	SARS-CoV-2 accessory proteins reveal distinct serological signatures in children. Nature Communications, 2022, 13, .	12.8	22
23	An early warning system for emerging SARS-CoV-2 variants. Nature Medicine, 2022, 28, 1110-1115.	30.7	47
24	Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections. Emerging Microbes and Infections, 2022, 11, 1742-1750.	6.5	43
25	Natural Reassortment of Eurasian Avian-like Swine H1N1 and Avian H9N2 Influenza Viruses in Pigs, China. Emerging Infectious Diseases, 2022, 28, 1509-1512.	4.3	4
26	Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents. Nature Communications, 2022, 13, .	12.8	42
27	Robustness of the Ferret Model for Influenza Risk Assessment Studies: a Cross-Laboratory Exercise. MBio, 2022, 13, .	4.1	12
28	T-cell responses to MERS coronavirus infection in people with occupational exposure to dromedary camels in Nigeria: an observational cohort study. Lancet Infectious Diseases, The, 2021, 21, 385-395.	9.1	50
29	Evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera. Journal of Clinical Microbiology, 2021, 59, .	3.9	102
30	Tropism of SARS-CoV-2, SARS-CoV, and Influenza Virus in Canine Tissue Explants. Journal of Infectious Diseases, 2021, 224, 821-830.	4.0	5
31	Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults. Npj Vaccines, 2021, 6, 25.	6.0	23
32	Intra-host variation and evolutionary dynamics of SARS-CoV-2 populations in COVID-19 patients. Genome Medicine, 2021, 13, 30.	8.2	88
33	Nowcasting epidemics of novel pathogens: lessons from COVID-19. Nature Medicine, 2021, 27, 388-395.	30.7	32
34	Kennedy F Shortridge PhD (April 6, 1941 to November 8, 2020): Obituary. Influenza and Other Respiratory Viruses, 2021, 15, 323-325.	3.4	2
35	Dynamics of B cell repertoires and emergence of cross-reactive responses in patients with different severities of COVID-19. Cell Reports, 2021, 35, 109173.	6.4	46
36	Introduction of ORF3a-Q57H SARS-CoV-2 Variant Causing Fourth Epidemic Wave of COVID-19, Hong Kong, China. Emerging Infectious Diseases, 2021, 27, 1492-1495.	4.3	33

#	Article	IF	CITATIONS
37	Phenotypic and Functional Characteristics of a Novel Influenza Virus Hemagglutinin-Specific Memory NK Cell. Journal of Virology, 2021, 95, .	3.4	8
38	Characterization of SARS-CoV-2 nucleocapsid protein reveals multiple functional consequences of the C-terminal domain. IScience, 2021, 24, 102681.	4.1	57
39	SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse. Nature Microbiology, 2021, 6, 821-823.	13.3	221
40	Homologous and heterologous serological response to the Nâ€ŧerminal domain of SARS oVâ€2 in humans and mice. European Journal of Immunology, 2021, 51, 2296-2305.	2.9	7
41	Phenotypic and genetic characterization of MERS coronaviruses from Africa to understand their zoonotic potential. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	20
42	SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection. Nature Communications, 2021, 12, 4678.	12.8	100
43	Influenza vaccine effectiveness against influenza-associated hospitalization in children in Hong Kong, 2010–2020. Vaccine, 2021, 39, 4842-4848.	3.8	5
44	SARS-CoV-2 Superspread in Fitness Center, Hong Kong, China, March 2021. Emerging Infectious Diseases, 2021, 27, 2230-2232.	4.3	24
45	Air travel-related outbreak of multiple SARS-CoV-2 variants. Journal of Travel Medicine, 2021, 28, .	3.0	14
46	Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. Lancet Microbe, The, 2021, 2, e423.	7.3	112
47	The first case study of wastewater-based epidemiology of COVID-19 in Hong Kong. Science of the Total Environment, 2021, 790, 148000.	8.0	50
48	Genetic Diversity of SARS-CoV-2 among Travelers Arriving in Hong Kong. Emerging Infectious Diseases, 2021, 27, 2666-2668.	4.3	8
49	Neutralizing antibody titres in SARS-CoV-2 infections. Nature Communications, 2021, 12, 63.	12.8	303
50	Limited onward transmission potential of reassortment genotypes from chickens co-infected with H9N2 and H7N9 avian influenza viruses. Emerging Microbes and Infections, 2021, 10, 2030-2041.	6.5	6
51	Ancestral sequence reconstruction pinpoints adaptations that enable avian influenza virus transmission in pigs. Nature Microbiology, 2021, 6, 1455-1465.	13.3	7
52	Domain-specific biochemical and serological characterization of SARS-CoV-2 nucleocapsid protein. STAR Protocols, 2021, 2, 100906.	1.2	1
53	Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection. EClinicalMedicine, 2021, 41, 101174.	7.1	57
54	The Effect of Influenza Vaccination History on Changes in Hemagglutination Inhibition Titers After Receipt of the 2015–2016 Influenza Vaccine in Older Adults in Hong Kong. Journal of Infectious Diseases, 2020, 221, 33-41.	4.0	11

#	Article	IF	CITATIONS
55	Maternal Antibodies Against Influenza in Cord Blood and Protection Against Laboratory-Confirmed Influenza in Infants. Clinical Infectious Diseases, 2020, 71, 1741-1748.	5.8	6
56	Comparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial. Clinical Infectious Diseases, 2020, 71, 1704-1714.	5.8	67
57	Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ, The, 2020, 371, m3862.	6.0	515
58	Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature, 2020, 583, 834-838.	27.8	1,185
59	Serologic Responses in Healthy Adult with SARS-CoV-2 Reinfection, Hong Kong, August 2020. Emerging Infectious Diseases, 2020, 26, 3076-3078.	4.3	41
60	SARS-CoV-2 in Quarantined Domestic Cats from COVID-19 Households or Close Contacts, Hong Kong, China. Emerging Infectious Diseases, 2020, 26, 3071-3074.	4.3	141
61	Phylogenetic Analysis of MERS-CoV in a Camel Abattoir, Saudi Arabia, 2016–2018. Emerging Infectious Diseases, 2020, 26, 3089-3091.	4.3	8
62	Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance, 2020, 25, .	7.0	5,865
63	Influenza vaccination effectiveness in preventing influenza hospitalization in children, Hong Kong, winter 2019/20. Vaccine, 2020, 38, 8078-8081.	3.8	4
64	Enterovirus genomic load and disease severity among children hospitalised with hand, foot and mouth disease. EBioMedicine, 2020, 62, 103078.	6.1	16
65	The Cause of Severe Acute Respiratory Syndrome: What Did We Learn from It?. Clinical Chemistry, 2020, 66, 1349-1350.	3.2	0
66	Infection of dogs with SARS-CoV-2. Nature, 2020, 586, 776-778.	27.8	580
67	Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science, 2020, 369, 1210-1220.	12.6	947
68	SARS-CoV-2 Virus Culture and Subgenomic RNA for Respiratory Specimens from Patients with Mild Coronavirus Disease. Emerging Infectious Diseases, 2020, 26, 2701-2704.	4.3	197
69	In-Flight Transmission of SARS-CoV-2. Emerging Infectious Diseases, 2020, 26, 2713-2716.	4.3	63
70	What can we expect from first-generation COVID-19 vaccines?. Lancet, The, 2020, 396, 1467-1469.	13.7	94
71	SARS-CoV-2 infection in conjunctival tissue – Authors' reply. Lancet Respiratory Medicine,the, 2020, 8, e58.	10.7	8
72	ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection. Nature Immunology, 2020, 21, 1293-1301.	14.5	198

#	Article	IF	CITATIONS
73	Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Eurosurveillance, 2020, 25, .	7.0	309
74	Heterosubtypic Protection Induced by a Live Attenuated Influenza Virus Vaccine Expressing Galactose-α-1,3-Galactose Epitopes in Infected Cells. MBio, 2020, 11, .	4.1	10
75	Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. Lancet Respiratory Medicine,the, 2020, 8, 687-695.	10.7	437
76	Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. Cell Reports, 2020, 31, 107725.	6.4	353
77	Multivariate analyses of codon usage of SARS-CoV-2 and other betacoronaviruses. Virus Evolution, 2020, 6, veaa032.	4.9	39
78	Harnessing the potential of blood donation archives for influenza surveillance and control. PLoS ONE, 2020, 15, e0233605.	2.5	1
79	Antibody Profiles in Mild and Severe Cases of COVID-19. Clinical Chemistry, 2020, 66, 1102-1104.	3.2	57
80	Presence of Influenza Virus on Touch Surfaces in Kindergartens and Primary Schools. Journal of Infectious Diseases, 2020, 222, 1329-1333.	4.0	18
81	Viral dynamics in mild and severe cases of COVID-19. Lancet Infectious Diseases, The, 2020, 20, 656-657.	9.1	1,421
82	Pandemic potential of highly pathogenic avian influenza clade 2.3.4.4 A(H5) viruses. Reviews in Medical Virology, 2020, 30, e2099.	8.3	70
83	Respiratory virus shedding in exhaled breath and efficacy of face masks. Nature Medicine, 2020, 26, 676-680.	30.7	1,753
84	Complete Genome Sequence of a 2019 Novel Coronavirus (SARS-CoV-2) Strain Isolated in Nepal. Microbiology Resource Announcements, 2020, 9, .	0.6	122
85	Emergence of a novel human coronavirus threatening human health. Nature Medicine, 2020, 26, 317-319.	30.7	125
86	Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. Clinical Chemistry, 2020, 66, 549-555.	3.2	1,098
87	Stability of SARS-CoV-2 in different environmental conditions. Lancet Microbe, The, 2020, 1, e10.	7.3	1,479
88	Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Research, 2020, 178, 104786.	4.1	737
89	Characterizing Emerging Canine H3 Influenza Viruses. PLoS Pathogens, 2020, 16, e1008409.	4.7	29
90	Kinetics of viral load and antibody response in relation to COVID-19 severity. Journal of Clinical Investigation, 2020, 130, 5235-5244.	8.2	501

#	Article	IF	CITATIONS
91	Variation by lineage in serum antibody responses to influenza B virus infections. PLoS ONE, 2020, 15, e0241693.	2.5	6
92	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0
93	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0
94	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0
95	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0
96	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0
97	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0
98	Therapeutic Implications of Human Umbilical Cord Mesenchymal Stromal Cells in Attenuating Influenza A(H5N1) Virus–Associated Acute Lung Injury. Journal of Infectious Diseases, 2019, 219, 186-196.	4.0	102
99	Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Dromedary Camels in Africa and Middle East. Viruses, 2019, 11, 717.	3.3	38
100	Effectiveness of Partial and Full Influenza Vaccination Among Children Aged <9 Years in Hong Kong, 2011–2019. Journal of Infectious Diseases, 2019, 220, 1568-1576.	4.0	7
101	Novel Avian Influenza A Virus Infections of Humans. Infectious Disease Clinics of North America, 2019, 33, 907-932.	5.1	34
102	Diversity of Dromedary Camel Coronavirus HKU23 in African Camels Revealed Multiple Recombination Events among Closely Related Betacoronaviruses of the Subgenus Embecovirus. Journal of Virology, 2019, 93, .	3.4	29
103	Tropism of influenza B viruses in human respiratory tract explants and airway organoids. European Respiratory Journal, 2019, 54, 1900008.	6.7	34
104	Risk Assessment of the Tropism and Pathogenesis of the Highly Pathogenic Avian Influenza A/H7N9 Virus Using Ex Vivo and In Vitro Cultures of Human Respiratory Tract. Journal of Infectious Diseases, 2019, 220, 578-588.	4.0	9
105	Serum anti-neuraminidase antibody responses in human influenza A(H1N1)pdm09 virus infections. Emerging Microbes and Infections, 2019, 8, 404-412.	6.5	9
106	Middle East respiratory syndrome coronavirus infection in non-camelid domestic mammals. Emerging Microbes and Infections, 2019, 8, 103-108.	6.5	42
107	Detection of Influenza and Other Respiratory Viruses in Air Sampled From a University Campus: A Longitudinal Study. Clinical Infectious Diseases, 2019, 70, 850-858.	5.8	15
108	Age-specific differences in the dynamics of protective immunity to influenza. Nature Communications, 2019, 10, 1660.	12.8	107

#	Article	IF	CITATIONS
109	Absence of adaptive evolution is the main barrier against influenza emergence in horses in Asia despite frequent virus interspecies transmission from wild birds. PLoS Pathogens, 2019, 15, e1007531.	4.7	12
110	Severe acute respiratory syndrome and other emerging severe respiratory viral infections. Respirology, 2019, 24, 410-412.	2.3	1
111	Seroprevalence of dogs in Hong Kong to human and canine influenza viruses. Veterinary Record Open, 2019, 6, e000327.	1.0	6
112	A novel luciferase immunosorbent assay performs better than a commercial enzyme-linked immunosorbent assay to detect MERS-CoV specific IgG in humans and animals. Biosafety and Health, 2019, 1, 134-143.	2.7	8
113	Smoking and Influenza-associated Morbidity and Mortality. Epidemiology, 2019, 30, 405-417.	2.7	60
114	Influenza Hemagglutination-inhibition Antibody Titer as a Mediator of Vaccine-induced Protection for Influenza B. Clinical Infectious Diseases, 2019, 68, 1713-1717.	5.8	40
115	West Nile virus infection in horses in Saudi Arabia (in 2013–2015). Zoonoses and Public Health, 2019, 66, 248-253.	2.2	10
116	Indirect protection from vaccinating children against influenza in households. Nature Communications, 2019, 10, 106.	12.8	19
117	Middle East respiratory syndrome coronavirus (MERS-CoV) neutralising antibodies in a high-risk human population, Morocco, November 2017 to January 2018. Eurosurveillance, 2019, 24, .	7.0	16
118	Defining the sizes of airborne particles that mediate influenza transmission in ferrets. Proceedings of the United States of America, 2018, 115, E2386-E2392.	7.1	71
119	MERS coronaviruses from camels in Africa exhibit region-dependent genetic diversity. Proceedings of the United States of America, 2018, 115, 3144-3149.	7.1	142
120	Whole transcriptome analysis reveals differential gene expression profile reflecting macrophage polarization in response to influenza A H5N1 virus infection. BMC Medical Genomics, 2018, 11, 20.	1.5	33
121	Cross-sectional study of MERS-CoV-specific RNA and antibodies in animals that have had contact with MERS patients in Saudi Arabia. Journal of Infection and Public Health, 2018, 11, 331-338.	4.1	38
122	Influenza A(H5N1) Virus Infection in a Child With Encephalitis Complicated by Obstructive Hydrocephalus. Clinical Infectious Diseases, 2018, 66, 136-139.	5.8	9
123	Genetic analysis of H7N9 highly pathogenic avian influenza virus in Guangdong, China, 2016–2017. Journal of Infection, 2018, 76, 93-96.	3.3	12
124	Effectiveness of influenza vaccination on influenza-associated hospitalisations over time among children in Hong Kong: a test-negative case-control study. Lancet Respiratory Medicine,the, 2018, 6, 925-934.	10.7	30
125	Combined use of live-attenuated and inactivated influenza vaccines to enhance heterosubtypic protection. Virology, 2018, 525, 73-82.	2.4	3
126	The effectiveness of influenza vaccination against medically-attended illnesses in Hong Kong across three years with different degrees of vaccine match, 2014–17. Vaccine, 2018, 36, 6117-6123.	3.8	3

#	Article	IF	CITATIONS
127	Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model. Antiviral Research, 2018, 155, 89-96.	4.1	51
128	Population Serologic Immunity to Human and Avian H2N2 Viruses in the United States and Hong Kong for Pandemic Risk Assessment. Journal of Infectious Diseases, 2018, 218, 1054-1060.	4.0	17
129	Replicative virus shedding in the respiratory tract of patients with Middle East respiratory syndrome coronavirus infection. International Journal of Infectious Diseases, 2018, 72, 8-10.	3.3	17
130	Influenza. Nature Reviews Disease Primers, 2018, 4, 3.	30.5	880
131	Swine influenza viruses in Northern Vietnam in 2013–2014. Emerging Microbes and Infections, 2018, 7, 1-16.	6.5	19
132	Human Clade 2.3.4.4 A/H5N6 Influenza Virus Lacks Mammalian Adaptation Markers and Does Not Transmit via the Airborne Route between Ferrets. MSphere, 2018, 3, .	2.9	42
133	Recognition of Double-Stranded RNA and Regulation of Interferon Pathway by Toll-Like Receptor 10. Frontiers in Immunology, 2018, 9, 516.	4.8	71
134	Incidence of influenza A(H3N2) virus infections in Hong Kong in a longitudinal sero-epidemiological study, 2009-2015. PLoS ONE, 2018, 13, e0197504.	2.5	14
135	Avian influenza A H7N9 virus infects human astrocytes and neuronal cells and induces inflammatory immune responses. Journal of NeuroVirology, 2018, 24, 752-760.	2.1	13
136	Tropism, replication competence, and innate immune responses of influenza virus: an analysis of human airway organoids and ex-vivo bronchus cultures. Lancet Respiratory Medicine,the, 2018, 6, 846-854.	10.7	99
137	Protection by universal influenza vaccine is mediated by memory CD4 T cells. Vaccine, 2018, 36, 4198-4206.	3.8	27
138	Use of influenza antivirals in patients hospitalized in Hong Kong, 2000-2015. PLoS ONE, 2018, 13, e0190306.	2.5	2
139	Lack of serological evidence of Middle East respiratory syndrome coronavirus infection in virus exposed camel abattoir workers in Nigeria, 2016. Eurosurveillance, 2018, 23, .	7.0	21
140	Interim estimate of influenza vaccine effectiveness in hospitalised children, Hong Kong, 2017/18. Eurosurveillance, 2018, 23, .	7.0	11
141	Viral shedding and transmission potential of asymptomatic and pauci-symptomatic influenza virus infections in the community. Clinical Infectious Diseases, 2017, 64, ciw841.	5.8	137
142	Tropism and innate host responses of influenza A/H5N6 virus: an analysis of <i>exÂvivo</i> and <i>in vitro</i> cultures of the human respiratory tract. European Respiratory Journal, 2017, 49, 1601710.	6.7	27
143	Population-Based Pediatric Hospitalization Burden of Lineage-Specific Influenza B in Hong Kong, 2004–2014. Clinical Infectious Diseases, 2017, 65, 300-307.	5.8	14
144	The PB2 mutation with lysine at 627 enhances the pathogenicity of avian influenza (H7N9) virus which belongs to a non-zoonotic lineage. Scientific Reports, 2017, 7, 2352.	3.3	13

#	Article	IF	CITATIONS
145	Replication of H9 influenza viruses in the human ex vivo respiratory tract, and the influence of neuraminidase on virus release. Scientific Reports, 2017, 7, 6208.	3.3	7
146	Relative incidence and individual-level severity of seasonal influenza A H3N2 compared with 2009 pandemic H1N1. BMC Infectious Diseases, 2017, 17, 337.	2.9	37
147	Longitudinal study of Middle East Respiratory Syndrome coronavirus infection in dromedary camel herds in Saudi Arabia, 2014–2015. Emerging Microbes and Infections, 2017, 6, 1-7.	6.5	59
148	CLEC5A-Mediated Enhancement of the Inflammatory Response in Myeloid Cells Contributes to Influenza Virus Pathogenicity <i>In Vivo</i> . Journal of Virology, 2017, 91, .	3.4	41
149	Epidemiological features of influenza circulation in swine populations: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0179044.	2.5	33
150	MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015. Emerging Infectious Diseases, 2017, 23, 1079-1084.	4.3	204
151	A46â \in fMERS-CoV in Arabian camels in Africa and Central Asia. Virus Evolution, 2017, 3, .	4.9	2
152	Risk factors for MERS coronavirus infection in dromedary camels in Burkina Faso, Ethiopia, and Morocco, 2015. Eurosurveillance, 2017, 22, .	7.0	58
153	Absence of Middle East Respiratory Syndrome Coronavirus in Camelids, Kazakhstan, 2015. Emerging Infectious Diseases, 2016, 22, 555-557.	4.3	37
154	Individual Correlates of Infectivity of Influenza A Virus Infections in Households. PLoS ONE, 2016, 11, e0154418.	2.5	30
155	Association between the Severity of Influenza A(H7N9) Virus Infections and Length of the Incubation Period. PLoS ONE, 2016, 11, e0148506.	2.5	13
156	A Comparative Study of Clinical Presentation and Risk Factors for Adverse Outcome in Patients Hospitalised with Acute Respiratory Disease Due to MERS Coronavirus or Other Causes. PLoS ONE, 2016, 11, e0165978.	2.5	91
157	MERS-CoV at the Animal–Human Interface: Inputs on Exposure Pathways from an Expert-Opinion Elicitation. Frontiers in Veterinary Science, 2016, 3, 88.	2.2	19
158	Interpreting Seroepidemiologic Studies of Influenza in a Context of Nonbracketing Sera. Epidemiology, 2016, 27, 152-158.	2.7	12
159	Population seroprevalence of antibody to influenza A(H7N9)Âvirus, Guangzhou, China. BMC Infectious Diseases, 2016, 16, 632.	2.9	13
160	Age-specific genetic and antigenic variations of influenza A viruses in Hong Kong, 2013–2014. Scientific Reports, 2016, 6, 30260.	3.3	2
161	Hospital-based vaccine effectiveness against influenza B lineages, Hong Kong, 2009â^'14. Vaccine, 2016, 34, 2164-2169.	3.8	16
162	Interventions in live poultry markets for the control of avian influenza: A systematic review. One Health. 2016. 2. 55-64.	3.4	43

#	Article	IF	CITATIONS
163	Anti-inflammatory effects of indirubin derivatives on influenza A virus-infected human pulmonary microvascular endothelial cells. Scientific Reports, 2016, 6, 18941.	3.3	21
164	Evaluation of the human adaptation of influenza A/H7N9 virus in PB2 protein using human and swine respiratory tract explant cultures. Scientific Reports, 2016, 6, 35401.	3.3	18
165	Highly pathogenic avian influenza H5N1 virus delays apoptotic responses via activation of STAT3. Scientific Reports, 2016, 6, 28593.	3.3	29
166	Interventions to reduce zoonotic and pandemic risks from avian influenza in Asia. Lancet Infectious Diseases, The, 2016, 16, 252-258.	9.1	75
167	Human mesenchymal stromal cells reduce influenza A H5N1-associated acute lung injury in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3621-3626.	7.1	174
168	Pulmonary and central nervous system pathology in fatal cases of hand foot and mouth disease caused by enterovirus A71 infection. Pathology, 2016, 48, 267-274.	0.6	10
169	Determinants of serum 25-hydroxyvitamin D in Hong Kong. British Journal of Nutrition, 2015, 114, 144-151.	2.3	21
170	Absence of MERS-Coronavirus in Bactrian Camels, Southern Mongolia, November 2014. Emerging Infectious Diseases, 2015, 21, 1269-1271.	4.3	43
171	Clinical, Virological and Immunological Features from Patients Infected with Re-Emergent Avian-Origin Human H7N9 Influenza Disease of Varying Severity in Guangdong Province. PLoS ONE, 2015, 10, e0117846.	2.5	28
172	Impact of the 2009 H1N1 Pandemic on Age-Specific Epidemic Curves of Other Respiratory Viruses: A Comparison of Pre-Pandemic, Pandemic and Post-Pandemic Periods in a Subtropical City. PLoS ONE, 2015, 10, e0125447.	2.5	31
173	Age-specific epidemic waves of influenza and respiratory syncytial virus in a subtropical city. Scientific Reports, 2015, 5, 10390.	3.3	21
174	Influenza A Virus Shedding and Infectivity in Households. Journal of Infectious Diseases, 2015, 212, 1420-1428.	4.0	92
175	Absence of MERS-CoV antibodies in feral camels in Australia: Implications for the pathogen's origin and spread. One Health, 2015, 1, 76-82.	3.4	37
176	International Laboratory Comparison of Influenza Microneutralization Assays for A(H1N1)pdm09, A(H3N2), and A(H5N1) Influenza Viruses by CONSISE. Vaccine Journal, 2015, 22, 957-964.	3.1	41
177	Association of Oseltamivir Treatment With Virus Shedding, Illness, and Household Transmission of Influenza Viruses. Journal of Infectious Diseases, 2015, 212, 391-396.	4.0	20
178	Transmission of H7N9 Influenza Viruses with a Polymorphism at PB2 Residue 627 in Chickens and Ferrets. Journal of Virology, 2015, 89, 9939-9951.	3.4	26
179	A more detailed picture of the epidemiology of Middle East respiratory syndrome coronavirus. Lancet Infectious Diseases, The, 2015, 15, 495-497.	9.1	32
180	Modulation of sterol biosynthesis regulates viral replication and cytokine production in influenza A virus infected human alveolar epithelial cells. Antiviral Research, 2015, 119, 1-7.	4.1	13

#	Article	IF	CITATIONS
181	Passive Immunotherapy with Dromedary Immune Serum in an Experimental Animal Model for Middle East Respiratory Syndrome Coronavirus Infection. Journal of Virology, 2015, 89, 6117-6120.	3.4	64
182	Lack of Middle East Respiratory Syndrome Coronavirus Transmission from Infected Camels. Emerging Infectious Diseases, 2015, 21, 699-701.	4.3	75
183	Sparse evidence of MERS ―C o V infection among animal workers living in S outhern S audi A rabia during 2012. Influenza and Other Respiratory Viruses, 2015, 9, 64-67.	3.4	31
184	Reply to Collignon et al. Clinical Infectious Diseases, 2015, 60, 489-490.	5.8	0
185	Generation of Live Attenuated Influenza Virus by Using Codon Usage Bias. Journal of Virology, 2015, 89, 10762-10773.	3.4	38
186	Comparative mutational analyses of influenza A viruses. Rna, 2015, 21, 36-47.	3.5	16
187	Population-Based Hospitalization Burden of Influenza A Virus Subtypes and Antigenic Drift Variants in Children in Hong Kong (2004–2011). PLoS ONE, 2014, 9, e92914.	2.5	14
188	Substitution at Aspartic Acid 1128 in the SARS Coronavirus Spike Glycoprotein Mediates Escape from a S2 Domain-Targeting Neutralizing Monoclonal Antibody. PLoS ONE, 2014, 9, e102415.	2.5	30
189	Absence of Detectable Influenza RNA Transmitted via Aerosol during Various Human Respiratory Activities – Experiments from Singapore and Hong Kong. PLoS ONE, 2014, 9, e107338.	2.5	21
190	Incidence of Influenza Virus Infections in Children in Hong Kong in a 3-Year Randomized Placebo-Controlled Vaccine Study, 2009-2012. Clinical Infectious Diseases, 2014, 59, 517-524.	5.8	46
191	Inferring Influenza Infection Attack Rate from Seroprevalence Data. PLoS Pathogens, 2014, 10, e1004054.	4.7	46
192	MERS Coronaviruses in Dromedary Camels, Egypt. Emerging Infectious Diseases, 2014, 20, 1049-1053.	4.3	259
193	Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution. Emerging Microbes and Infections, 2014, 3, 1-9.	6.5	32
194	Association Between Antibody Titers and Protection Against Influenza Virus Infection Within Households. Journal of Infectious Diseases, 2014, 210, 684-692.	4.0	83
195	Glycomic Characterization of Respiratory Tract Tissues of Ferrets. Journal of Biological Chemistry, 2014, 289, 28489-28504.	3.4	82
196	Social contacts and the locations in which they occur as risk factors for influenza infection. Proceedings of the Royal Society B: Biological Sciences, 2014, 281, 20140709.	2.6	48
197	Effect of the PB2 and M Genes on the Replication of H6 Influenza Virus in Chickens. Influenza Research and Treatment, 2014, 2014, 1-6.	1.5	4
198	Expansion of Genotypic Diversity and Establishment of 2009 H1N1 Pandemic-Origin Internal Genes in Pigs in China. Journal of Virology, 2014, 88, 10864-10874.	3.4	79

#	Article	IF	CITATIONS
199	Anti-inflammatory and antiviral effects of indirubin derivatives in influenza A (H5N1) virus infected primary human peripheral blood-derived macrophages and alveolar epithelial cells. Antiviral Research, 2014, 106, 95-104.	4.1	34
200	Fatal H7N9 pneumonia complicated by viral infection of a prosthetic cardiac valve – An autopsy study. Journal of Clinical Virology, 2014, 61, 466-469.	3.1	7
201	Human H7N9 and H5N1 Influenza Viruses Differ in Induction of Cytokines and Tissue Tropism. Journal of Virology, 2014, 88, 12982-12991.	3.4	36
202	Tropism and replication of Middle East respiratory syndrome coronavirus from dromedary camels in the human respiratory tract: an in-vitro and ex-vivo study. Lancet Respiratory Medicine,the, 2014, 2, 813-822.	10.7	86
203	Generation and characterization of influenza A viruses with altered polymerase fidelity. Nature Communications, 2014, 5, 4794.	12.8	94
204	The effectiveness of influenza vaccination in preventing hospitalizations in children in Hong Kong, 2009–2013. Vaccine, 2014, 32, 5278-5284.	3.8	56
205	Influenza A viruses with different amino acid residues at PB2-627 display distinct replication properties in vitro and in vivo : Revealing the sequence plasticity of PB2-627 position. Virology, 2014, 468-470, 545-555.	2.4	18
206	Towards improving clinical management of Middle East respiratory syndrome coronavirus infection. Lancet Infectious Diseases, The, 2014, 14, 544-546.	9.1	30
207	Modes of Transmission of Influenza B Virus in Households. PLoS ONE, 2014, 9, e108850.	2.5	9
208	Use of ex vivo and in vitro cultures of the human respiratory tract to study the tropism and host responses of highly pathogenic avian influenza A (H5N1) and other influenza viruses. Virus Research, 2013, 178, 133-145.	2.2	42
209	Tropism and innate host responses of a novel avian influenza A H7N9 virus: an analysis of ex-vivo and in-vitro cultures of the human respiratory tract. Lancet Respiratory Medicine,the, 2013, 1, 534-542.	10.7	88
210	Estimation of the Association Between Antibody Titers and Protection Against Confirmed Influenza Virus Infection in Children. Journal of Infectious Diseases, 2013, 208, 1320-1324.	4.0	66
211	Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002–2012 shows need for continued monitoring. Antiviral Research, 2013, 98, 297-304.	4.1	105
212	Infection Fatality Risk of the Pandemic A(H1N1)2009 Virus in Hong Kong. American Journal of Epidemiology, 2013, 177, 834-840.	3.4	83
213	Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor. Emerging Microbes and Infections, 2013, 2, 1-9.	6.5	29
214	Protective Efficacy Against Pandemic Influenza of Seasonal Influenza Vaccination in Children in Hong Kong: A Randomized Controlled Trial. Clinical Infectious Diseases, 2012, 55, 695-702.	5.8	60
215	Long-term evolution and transmission dynamics of swine influenza A virus. Nature, 2011, 473, 519-522.	27.8	219
216	Epidemiological Characteristics of 2009 (H1N1) Pandemic Influenza Based on Paired Sera from a Longitudinal Community Cohort Study. PLoS Medicine, 2011, 8, e1000442.	8.4	103

#	Article	IF	CITATIONS
217	Inhibition of Human Natural Killer Cell Activity by Influenza Virions and Hemagglutinin. Journal of Virology, 2010, 84, 4148-4157.	3.4	83
218	Protective Efficacy of Seasonal Influenza Vaccination against Seasonal and Pandemic Influenza Virus Infection during 2009 in Hong Kong. Clinical Infectious Diseases, 2010, 51, 1370-1379.	5.8	139
219	Induction of Proinflammatory Cytokines in Primary Human Macrophages by Influenza A Virus (H5N1) Is Selectively Regulated by IFN Regulatory Factor 3 and p38 MAPK. Journal of Immunology, 2009, 182, 1088-1098.	0.8	135
220	Influenza Virus Directly Infects Human Natural Killer Cells and Induces Cell Apoptosis. Journal of Virology, 2009, 83, 9215-9222.	3.4	129
221	DAS181 Inhibits H5N1 Influenza Virus Infection of Human Lung Tissues. Antimicrobial Agents and Chemotherapy, 2009, 53, 3935-3941.	3.2	66
222	Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature, 2009, 459, 1122-1125.	27.8	1,870
223	Emergence of a novel swine-origin influenza A virus (S-OIV) H1N1 virus in humans. Journal of Clinical Virology, 2009, 45, 169-173.	3.1	302
224	Avian Influenza H5â€Containing Virusâ€Like Particles (VLPs): Hostâ€Cell Receptor Specificity by STD NMR Spectroscopy. Angewandte Chemie - International Edition, 2008, 47, 1910-1912.	13.8	51
225	Avian influenza: Update on pathogenesis and laboratory diagnosis. Respirology, 2008, 13, S14-S18.	2.3	8
226	Evolving complexities of influenza virus and its receptors. Trends in Microbiology, 2008, 16, 149-157.	7.7	185
227	Identification of Oxidative Stress and Toll-like Receptor 4 Signaling as a Key Pathway of Acute Lung Injury. Cell, 2008, 133, 235-249.	28.9	1,164
228	Update on Avian Influenza A (H5N1) Virus Infection in Humans. New England Journal of Medicine, 2008, 358, 261-273.	27.0	814
229	Antigenic Profile of Avian H5N1 Viruses in Asia from 2002 to 2007. Journal of Virology, 2008, 82, 1798-1807.	3.4	100
230	H5-Type Influenza Virus Hemagglutinin Is Functionally Recognized by the Natural Killer-Activating Receptor NKp44. Journal of Virology, 2008, 82, 2028-2032.	3.4	71
231	Preliminary Findings of a Randomized Trial of Non-Pharmaceutical Interventions to Prevent Influenza Transmission in Households. PLoS ONE, 2008, 3, e2101.	2.5	145
232	Comparison of the NucliSens easyMAG and Qiagen BioRobot 9604 Nucleic Acid Extraction Systems for Detection of RNA and DNA Respiratory Viruses in Nasopharyngeal Aspirate Samples. Journal of Clinical Microbiology, 2008, 46, 2195-2199.	3.9	47
233	Appendix: Representative Compounds with Inhibitory Activity Against SARS CoV or Other CoVs in vitro. , 2008, , 255-256.		0

#	Article	IF	CITATIONS
235	The Effects of Air Pollution on Mortality in Socially Deprived Urban Areas in Hong Kong, China. Environmental Health Perspectives, 2008, 116, 1189-1194.	6.0	112
236	Is Exercise Protective Against Influenza-Associated Mortality?. PLoS ONE, 2008, 3, e2108.	2.5	74
237	Avian Influenza A Virus (H5N1) Outbreaks, Kuwait, 2007. Emerging Infectious Diseases, 2008, 14, 958-961.	4.3	20
238	Detection of SARS Coronavirus in Humans and Animals by Conventional and Quantitative (Real Time) Reverse Transcription Polymerase Chain Reactions. Methods in Molecular Biology, 2008, 454, 61-72.	0.9	7
239	Pneumonia research to reduce childhood mortality in the developing world. Journal of Clinical Investigation, 2008, 118, 1291-1300.	8.2	132
240	Differential onset of apoptosis in influenza A virus H5N1- and H1N1-infected human blood macrophages. Journal of General Virology, 2007, 88, 1275-1280.	2.9	68
241	Immunogenicity and Safety of Intradermal Influenza Immunization at a Reduced Dose in Healthy Children. Pediatrics, 2007, 119, 1076-1082.	2.1	59
242	Association of ICAM3 Genetic Variant with Severe Acute Respiratory Syndrome. Journal of Infectious Diseases, 2007, 196, 271-280.	4.0	33
243	Severe acute respiratory syndrome coronavirus Orf3a protein interacts with caveolin. Journal of General Virology, 2007, 88, 3067-3077.	2.9	68
244	Avian Influenza Virus (H5N1): a Threat to Human Health. Clinical Microbiology Reviews, 2007, 20, 243-267.	13.6	802
245	Sialic acid receptor detection in the human respiratory tract: evidence for widespread distribution of potential binding sites for human and avian influenza viruses. Respiratory Research, 2007, 8, 73.	3.6	250
246	Effect of Interventions on Influenza A (H9N2) Isolation in Hong Kong's Live Poultry Markets, 1999–2005. Emerging Infectious Diseases, 2007, 13, 1340-1347.	4.3	54
247	Poultry Drinking Water Used for Avian Influenza Surveillance. Emerging Infectious Diseases, 2007, 13, 1380-1382.	4.3	56
248	The association of RANTES polymorphism with severe acute respiratory syndrome in Hong Kong and Beijing Chinese. BMC Infectious Diseases, 2007, 7, 50.	2.9	39
249	Reliable universal RT-PCR assays for studying influenza polymerase subunit gene sequences from all 16 haemagglutinin subtypes. Journal of Virological Methods, 2007, 142, 218-222.	2.1	52
250	The interferon gamma gene polymorphism +874 A/T is associated with severe acute respiratory syndrome. BMC Infectious Diseases, 2006, 6, 82.	2.9	83
251	Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection. Nature Genetics, 2006, 38, 38-46.	21.4	127
252	Three Indonesian Clusters of H5N1 Virus Infection in 2005. New England Journal of Medicine, 2006, 355, 2186-2194.	27.0	321

#	Article	IF	CITATIONS
253	Time Course and Cellular Localization of SARS-CoV Nucleoprotein and RNA in Lungs from Fatal Cases of SARS. PLoS Medicine, 2006, 3, e27.	8.4	127
254	Sensitive and Inexpensive Molecular Test for Falciparum Malaria: Detecting Plasmodium falciparum DNA Directly from Heat-Treated Blood by Loop-Mediated Isothermal Amplification,. Clinical Chemistry, 2006, 52, 303-306.	3.2	422
255	Pathogenesis of avian flu H5N1 and SARS. Novartis Foundation Symposium, 2006, 279, 56-60; discussion 60-5, 216-9.	1.1	15
256	Pathogenesis of severe acute respiratory syndrome. Current Opinion in Immunology, 2005, 17, 404-410.	5.5	143
257	SARS Coronavirus Detection Methods. Emerging Infectious Diseases, 2005, 11, 1108-1111.	4.3	66
258	p38 Mitogen-Activated Protein Kinase-Dependent Hyperinduction of Tumor Necrosis Factor Alpha Expression in Response to Avian Influenza Virus H5N1. Journal of Virology, 2005, 79, 10147-10154.	3.4	125
259	SARS-CoV Antibody Prevalence in All Hong Kong Patient Contacts. Emerging Infectious Diseases, 2004, 10, 1653-1656.	4.3	72
260	Severe acute respiratory syndrome and dentistry. Journal of the American Dental Association, 2004, 135, 1292-1302.	1.5	119
261	The Severe Acute Respiratory Syndrome (SARS) Coronavirus NTPase/Helicase Belongs to a Distinct Class of 5′ to 3′ Viral Helicases. Journal of Biological Chemistry, 2003, 278, 39578-39582.	3.4	183
262	Children with Respiratory Disease Associated with Metapneumovirus in Hong Kong. Emerging Infectious Diseases, 2003, 9, 628-633.	4.3	381
263	NOSOCOMIAL OUTBREAK OF PARVOVIRUS B19 INFECTION IN A RENAL TRANSPLANT UNIT12. Transplantation, 2001, 71, 59-63.	1.0	52
264	Adult Croup: A Rare but More Severe Condition. Respiration, 2000, 67, 684-688.	2.6	30
265	Characterization of the Influenza A Virus Gene Pool in Avian Species in Southern China: Was H6N1 a Derivative or a Precursor of H5N1?. Journal of Virology, 2000, 74, 6309-6315.	3.4	204
266	Human herpesvirus-6 (HHV-6) and HHV-7 infections in bone marrow transplant recipients. Critical Reviews in Oncology/Hematology, 1999, 32, 187-196.	4.4	3
267	Early Diagnosis of Primary Human Herpesvirus 6 Infection in Childhood: Serology, Polymerase Chain Reaction, and Virus Load. Journal of Infectious Diseases, 1998, 178, 1250-1256.	4.0	74